The unique diagnostic tests utilize Mabs generated from the Company's proprietary Antigen-Free Mouse Colony, which generates high affinity Mabs that are difficult, or impossible, to acquire using conventional techniques. Growth is also expected from contract agreements to produce Mabs utilizing the Antigen Free technology in exchange for payments and royalties, such as the agreement reached with Trevigen, Inc. in April 1998. ABS has agreed to produce four monoclonal antibodies for Trevigen. In addition to payments and manufacturing rights, ABS will receive a 5% royalty on products developed under the Agreement. Moreover, Trevigen has agreed to screen a number of the Company's drug candidates to assess whether they influence apoptosis (programmed cell death), which plays a role in certain neurodegenerative disorders.